Survival outcome and impact of delayed imatinib therapy in gastric gastrointestinal stromal tumors

This research article evaluated survival outcomes in gastric gastrointestinal stromal tumor (GIST) patients and the impact of delayed imatinib therapy. The study found that delayed imatinib therapy negatively impacted disease-free survival (DFS) in high-risk patients. High-risk classification, smoking, prolonged operative time, and advanced tumor stage were associated with poor DFS. The study highlights the need for improved access to early TKI treatment.